Shuttle Pharmaceuticals Holdings, INC 8-K filings

Shuttle Pharmaceuticals plans to raise up to $4.5 million through a rights offering, with a significant portion backstopped by SRO LLC, to fund a diagnostics laboratory for prostate cancer research.

Shuttle Pharmaceuticals has acquired the PSMA-Boron invention, a potential theranostic agent for prostate cancer, from its inventors, Alan Kozikowski and Werner Tueckmantel.